Gilead Sciences, Inc (NASDAQ:GILD) to Promote John Martin To Become The New Chairman Of The Board Of Directors
Seed Mena And Jaguar Health Inc (NASDAQ:JAGX) Partner To Carry Out Tests On Equilevia™
December 19, 2017
Litecoin Founder Lee Predicts Future For Cryptocurrency
December 19, 2017
The stock of Gilead Sciences, Inc (NASDAQ:GILD) closed at $75.57 gaining 1.65% in yesterday’s trading session. The Executive Chairman of Gilead, John Martin, will in a short while transition his current role to take up the position of the company’s new Chairman of the Board of Directors. It was back in 2016 when he was named the company’s Executive Chairman thus surrendering the CEO position to John Milligan.
Dr. Martin served as the company’s CEO between 1996 to 2016.Record indicates that he made his entry into the company in 1990 where he became the Vice President of Research and Development. Serving in his capacity as CEO, the official achieved quite much with one of the achievements being building the company’s portfolio to 24 marketed products associated with about $32 billion in terms of the annual revenues.
The President and CEO of Gilead, Dr. Milligan, opined,” John’s scientific and business leadership has been notable for the development of Gilead’s portfolio of HIV and viral hepatitis medicines and commitment to worldwide access for patients. We are all grateful that he will continue to help guide the company as Chairman of the Board.”
Martin was recently interviewed by a number of reporters who were interested in understanding his reaction about the most recent development. He said that that was no mean achievement outlining that he deserved it considering the efforts he had put in to get the company to where it was at the moment.
He attested to the fact that the company on its way towards achieving immense business success had come across numerous challenges. He however took great pride in the fact that they had in several instances put themselves together as the company’s management and solved matters amicably.
According to him, challenges were sure to pop up from time to time. But what mattered were the strategies employed in dealing with them. He was happy about the new opportunity. Martin said he was going to use his rise in rank to do what was of the company’s best interest. All eyes are on him to see what he achieves.
